An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Carcinoma
Phase of Trial: Phase II
Latest Information Update: 18 Jun 2018
At a glance
- Drugs Cixutumumab (Primary) ; Cisplatin; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 18 Jul 2016 Status changed from active, no longer recruiting to completed.
- 24 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016.
- 28 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History